Globus Medical Director Stephen Zarrilli Exercises Options, Sells Shares

What Happened
Stephen T. Zarrilli, a director of Globus Medical (GMED), exercised stock options and sold shares on Aug 18, 2026. The filing shows an exercise that acquired 25,000 shares at $53.27 per share (cost ~$1,331,750) and an open-market sale of 25,000 shares at a weighted average price of $87.04 per share (proceeds ~$2,175,965). A separate derivative entry reports 25,000 shares disposed at $0.00 (see footnotes).

Key Details

• Date: 2026-08-18 (Form 4 filed 2026-08-19, timely)
• Exercise: 25,000 shares acquired @ $53.27 — $1,331,750
• Sale: 25,000 shares sold @ weighted avg $87.04 — $2,175,965 (prices ranged $86.92–$87.16; weighted avg reported per footnote)
• Derivative entry: 25,000 shares reported disposed at $0.00 (reported as a derivative transaction)
• Shares owned after the transactions: not disclosed in the provided excerpt
• Footnotes: F1 explains weighted-average sale price and availability of per-lot sale prices; F2 notes the options were granted Jan 22, 2020 and are fully vested
• No 10b5-1 plan or late-filing indication in this filing

Context
The sequence—option exercise and a contemporaneous market sale of shares—appears consistent with a cashless exercise or immediate sell-to-cover arrangement (exercise followed by sale). The 0.00 disposal line likely reflects a derivative settlement/adjustment; see footnotes for details. These are routine insider-reporting transactions; purchases typically carry more informational weight than sales, but the filing documents the execution and sale of vested options.